1. Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis 
Bruce C. Trapnell, Karen Maguiness, Gavin R. Graff, David Boyd, Katrin Beckmann, Steven Caras 
Journal of Cystic Fibrosis 
Volume 8, Issue 6, Pages (December 2009)
DOI: /j.jcf
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

2. Fig. 1 Study design and patient disposition. AE: adverse event.
Journal of Cystic Fibrosis 2009 8, DOI: ( /j.jcf )
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

3. Fig. 2
Individual subject data for (A) coefficient of fat absorption (CFA) and (B) coefficient of nitrogen absorption (CNA) during treatment with Creon or placebo.
Journal of Cystic Fibrosis 2009 8, DOI: ( /j.jcf )
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions

4. Fig. 3
Effect of Creon on abdominal pain (A, B), stool consistency (C, D), and flatulence (E, F), and Clinical Global Impression of Disease Severity (CGI) assessed by investigators (G) and by subjects (H).
Journal of Cystic Fibrosis 2009 8, DOI: ( /j.jcf )
Copyright © 2009 European Cystic Fibrosis Society. Terms and Conditions